Hypomethylating agents and chemotherapy in MDS

L Adès, V Santini - Best Practice & Research Clinical Haematology, 2013 - Elsevier
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower …
被引用次数：12 相关文章

Hypomethylating agents and chemotherapy in MDS

L Adès, V Santini - BAILLIERE'S BEST PRACTICE IN CLINICAL …, 2013 - flore.unifi.it
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower …

Hypomethylating agents and chemotherapy in MDS.

L Adès, V Santini - Best Practice & research. Clinical Haematology, 2013 - europepmc.org
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower …

Hypomethylating agents and chemotherapy in MDS

L Adès, V Santini - Best practice & research. Clinical …, 2013 - pubmed.ncbi.nlm.nih.gov
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower …

Hypomethylating agents and chemotherapy in MDS

L Adès, V Santini - Best Practice & Research Clinical Haematology, 2013 - infona.pl
Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower …